

Special Issue

Upper Gastrointestinal Cancer and Liver Cirrhosis

Message from the Guest Editor

Patients with liver cirrhosis have an increased risk of extrahepatic cancers, but life expectancy of cirrhotic patients has increased thanks to antiviral drugs and liver transplantation. Today, cancer and not liver disease, could be the survival limiting factor. Liver cirrhosis is also a major limit to cancer therapy, because of impaired hepatic function and greatly increased surgical risk. Management of these patients is demanding, needs involvement of a multidisciplinary team, and requires careful calculation of the risk-benefit ratio. This Special Issue of *Cancers* addresses the relations between upper gastrointestinal cancer and liver cirrhosis. We invite experts to submit research articles and reviews on all aspects of the complex management of these patients.

Guest Editor

Dr. Michele Valmasoni

Center for Esophageal Diseases, Clinica Chirurgica 3, Department of Surgery, Oncology and Gastroenterology, Padova University Hospital, 35128 Padova, Italy.

Deadline for manuscript submissions

closed (28 February 2022)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



mdpi.com/si/52459

Cancers
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.5
CiteScore 8.0
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)